Neoleukin Therapeutics
(NASDAQ) NLTX
Neoleukin Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$0.00
Net Income (TTM)
$90.35M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
NLTX News
NLTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Neoleukin Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
107
CEO
Rachel L. McMinn, PhD
Website
www.neurogene.comHeadquarters
Seattle, WA 98102, US
NLTX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-33%
Return on Capital
-38%
Return on Assets
-31%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$103.33M
EBITDA
$103.33M
Operating Cash Flow
$77.17M
Capital Expenditure
$1.18M
Free Cash Flow
$78.36M
Cash & ST Invst.
$269.01M
Total Debt
$9.89M
Neoleukin Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$0.00
-100.0%
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
7
N/A
Net Income
$24.73M
+48.9%
EBITDA
$27.53M
+56.0%
Quarterly Fundamentals
Net Cash
$259.12M
-13.6%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$6.83M
-27.6%
Short Term Debt
$3.06M
+2.2%
Return on Assets
-31.31%
N/A
Return on Invested Capital
-37.96%
N/A
Free Cash Flow
$17.56M
+64.5%
Operating Cash Flow
$17.43M
+64.6%